Navigation Links
Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Date:12/10/2009

ard chemotherapy."

For the study published in The Lancet Oncology, researchers analyzed 367 tumor samples from node-positive, estrogen receptor-positive breast cancer patients who participated in the SWOG/Breast Cancer Intergroup of North America trial that evaluated CAF chemotherapy followed by tamoxifen versus tamoxifen-alone, to determine the prognostic and predictive effects of the Oncotype DX Recurrence Score.

The Recurrence Score was highly prognostic in the tamoxifen-alone arm (p=0.006) and demonstrated predictive ability in those patients treated with chemotherapy followed by tamoxifen. Specifically the study found no chemotherapy benefit in the low Recurrence Score group (log-rank p=0.97; HR=1.02); however, there was significant disease-free survival improvement for the high Recurrence Score group (log-rank p=0.03; HR=0.59).

"Since these data were originally presented in 2007, I have used Oncotype DX to help make treatment recommendations for select node-positive patients in my clinical practice," said Eric Winer, M.D., Chief, Division of Women's Cancers at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. "It is imperative that we bring our new molecular insights into clinical practice so that we can optimize and individualize treatment for every patient with breast cancer."

Additional data analyses presented at the CTRC-AACR San Antonio Breast Cancer Symposium today reinforced the conclusion that chemotherapy does not appear to benefit patients with either 1-3 or 4 or more positive nodes for disease-free survival over 10 years, if their tumors have a low Recurrence Score. There was no breast cancer specific survival (BCSS) benefit from chemotherapy in either the low (log-rank p=0.56) or intermediate (log-rank p=0.89) Recurrence Score categories; however, chemotherapy resulted in superior BCSS in the high Recurrence Score category (log-rank p=0.033).


'/>"/>
SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... 23, 2013  The need to add tissue ... was highlighted prominently at the 108 th ... in San Diego.  According to SonaCare Medical, a ... (HIFU) technology, the need for image-guided technologies to ... to consider minimally invasive ablative treatments, was addressed ...
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... 17, 2007 - ProNAi Therapeutics,Inc., a biopharmaceutical ... based on DNA interference (DNAi), today,announced that ... demonstrated preclinical in vivo efficacy in,xenograft mice ... including curative,events for difficult-to-treat Burkitt's Lymphoma., Dr. ...
... April 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced ... 2 clinical trial of the triplet combination ... in the,first-line treatment of advanced non-small cell ... clinically significant,improvement in both progression-free survival and ...
Cached Medicine Technology:ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... have a great deal of control over their level ... their weight, yet far fewer are actually taking that ... International Food Information Council (IFIC) Foundation’s 2013 Food & ... of respondents say it’s possible to have “a great ...
(Date:5/23/2013)... Chicago, IL (PRWEB) May 23, 2013 ... the fifth anniversary of its popular and only free ... and a successful continuing resource for OCD sufferers, the ... anxiety, OCD, and related disorders. This allows group ... Therapy, and Exposure and Response Prevention. , “Participants in ...
(Date:5/23/2013)... (HealthDay News) -- Schools should ensure that kids ... each day to support their health and boost ... Although previous studies show 60 minutes ... and development, it,s estimated that only about 50 ... recommendation, according to the report from the Institute ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... as badly as methamphetamine or crack cocaine, a new ... ,meth mouth, or ,coke mouth, it is startling to ... less the same," said Dr. Mohamed Bassiouny, a professor ... Dentistry in Philadelphia. Methamphetamine, crack cocaine and soda ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
... Scientific understanding and medical treatments for autism spectrum disorders ... but much remains to be done, say experts from ... of Philadelphia who published a scientific review of the ... by autism researchers throughout the world, and give our ...
... , BALTIMORE, Oct. 14 Lynn R. Chincheck, DDS, and ... breast cancer on Sunday, Oct. 18, as part of Baltimore,s ... participate by patients who have battled breast cancer, Team Chincheck ... , "After meeting several patients who have been affected by ...
... Advice Networks , the nation,s leading provider of physician ... track consumer purchase behavior, not just purchase intent, for ... their revenue and justify investments designed to capture market ... their health messages to purchase volume. To address this ...
... Almost a billion people across the planet do not have ... a mere $5 can give one person clean water for ... to doing good and supporting good in communities through a ... bringing clean and safe drinking water to people in developing ...
... Cardium Therapeutics (NYSE Amex: CXM ) today ... product candidate Excellagen(TM), a collagen-based topical gel for use ... in patients with chronic or non-chronic diabetic foot ulcers. ... study findings reported today from the Excellarate(TM) Phase 2b ...
... ... it will feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at ... October 17-21. , ... Ann Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of ...
Cached Medicine News:Health News:Experts summarize state of the science in autism disorders 2Health News:Team Chincheck Goes Miles for Smiles 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3Health News:Tom's of Maine and charity: water Team Up to Fund Global Clean Water Projects With Instant, Mobile Donation Campaign 2Health News:Tom's of Maine and charity: water Team Up to Fund Global Clean Water Projects With Instant, Mobile Donation Campaign 3Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 2Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 3Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 4Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 5Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 6Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 7Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 8Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3
... The Macula Plus® 5.5 ... observation of the optic ... Use it with your ... detecting choroidal neovascular membranes, ...
... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...
... is based on the C6 peptide antigen, a ... VlsE. This peptide has been shown to ... all of the antigenic reactivity of the whole ... C6 peptide is a sensitive and specific marker ...
First to USA-market, this revolutionary technology combines CBC and CRP analysis for stat results of 17 parameters within 4.5 minutes!...
Medicine Products: